Abstract: The present disclosure is directed to the use of inhibitors of glutamate metabolism to treat cancers that have mutations in ARID1A. Thus, in accordance with the present disclosure, there is provided a method of treating a subject determined to have an ARIDIA-mutated cancer, pre-cancer or benign tumor comprising administering to said subject at least one inhibitor of glutamate metabolism.
Type:
Application
Filed:
September 11, 2020
Publication date:
November 3, 2022
Applicant:
The Wistar Institute of Anatomy and Biology
Abstract: Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
October 11, 2022
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
Abstract: This disclosure provides methods for enhancing antitumor cytotoxicity of immune cells by introducing to the immune cells a genetic modification that comprises overexpression of RHEB or a functional fragment thereof, overexpression of LAMP 1-RHEB or a functional fragment thereof, overexpression of CA9 or a functional fragment thereof, overexpression of NHE1 or a functional fragment thereof, or combination thereof.
Type:
Application
Filed:
July 24, 2020
Publication date:
August 25, 2022
Applicants:
Ludwig Institute for Cancer Research Ltd, The Wistar Institute
Inventors:
Zandra Walton, Zachary Stine, Yaoyu Gong, Chi Van Dang
Abstract: Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Epstein-Barr virus (EBV) antigen. Immunomodulatory methods and methods of inducing an immune response against EBV are disclosed. Method of treating infection by EBV and methods of treating or preventing a disease or disorder associated with EBV are disclosed. Modified consensus EBV antigens are disclosed.
Type:
Grant
Filed:
February 15, 2019
Date of Patent:
July 26, 2022
Assignee:
THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
Type:
Grant
Filed:
August 27, 2021
Date of Patent:
April 5, 2022
Assignees:
Virion Therapeutics, LLC, The Wistar Institute
Inventors:
Hildegund C J Ertl, Colin Stephen Magowan
Abstract: A nucleic acid sequence is provided that encodes a chimeric protein comprising a ligand that comprises a naturally occurring or modified follicle stimulating hormone sequence, e.g., an FSH? sequence, or fragment thereof, which ligand binds to human follicle stimulating hormone (FSH) receptor, linked to either (a) a nucleic acid sequence that encodes an extracellular hinge domain, a transmembrane domain, a co-stimulatory signaling region, and a signaling endodomain; or (b) a nucleic acid sequence that encodes a ligand that binds to NKG2D. The vector containing the nucleic acid sequence, the chimeric proteins so encoded, and modified T cells expressing the chimeric protein, as well as method of using these compositions for the treatment of FSHR-expressing cancers or tumor cells are also provided.
Type:
Grant
Filed:
February 21, 2019
Date of Patent:
February 15, 2022
Assignee:
The Wistar Institute of Anatomy and Biology
Inventors:
Alfredo Perales-Puchalt, Jose R. Conejo-Garcia
Abstract: The invention relates, in certain aspects, to developable forms of certain compounds that are useful to treat and/or prevent EBV infection and related conditions in a subject. The invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
Type:
Grant
Filed:
May 16, 2019
Date of Patent:
February 8, 2022
Assignee:
The Wistar Institute
Inventors:
Troy E. Messick, Paul M. Lieberman, Garry R. Smith, Arlindo L. Castelhano
Abstract: Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
Type:
Grant
Filed:
July 23, 2019
Date of Patent:
February 8, 2022
Assignee:
The Wistar Institute of Anatomy and Biology
Inventors:
Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Venkata Velvadapu
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV virus infection in a subject using said composition and method of generation.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
January 25, 2022
Assignees:
THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, INOVIO PHARMACEUTICALS, INC.
Inventors:
David Weiner, Trevor R F Smith, Kar Muthumani
Abstract: The present disclosure provides compounds of the formula (I) wherein these compounds contain a ligand which binds to one or more target proteins such as CDK4 or CDK6 and a ligand which binds to the machinery associated with the ubiquitinating protein machinery. Also provided herein are methods of using these compounds in compositions or methods of treating patients with these compounds for the treatment of a disease or disorders such as cancer.
Type:
Application
Filed:
October 30, 2019
Publication date:
January 6, 2022
Applicants:
The Wistar Institute of Anatomy and Biology, Thomas Jefferson University
Inventors:
Joseph SALVINO, Bruno CALABRETTA, Marco DE DOMINICI, You Cai XIAO
Abstract: Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.
Type:
Grant
Filed:
May 10, 2019
Date of Patent:
December 28, 2021
Assignee:
The Wistar Institute of Anatomy and Biology
Inventors:
Hildegund C. J. Ertl, Marcio O. Lasaro, Luis C. S. Ferreira
Abstract: Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.
Type:
Grant
Filed:
February 16, 2017
Date of Patent:
December 28, 2021
Assignee:
The Wistar Institute of Anatomy and Biology
Abstract: The disclosure relates to methods of manufacturing individualized vaccines that comprise nucleic acid molecules that encode one or more neoantigens specific for antigens that are expressed by a tumor in a subject. Compositions comprising coding regions encoding neoantigens organized in a pattern of nucleic acid sequences are also disclosed as well as methods of immunizing a subject using the same.
Type:
Application
Filed:
May 28, 2019
Publication date:
November 25, 2021
Applicants:
THE WISTAR INSTITUTE, INOVIO PHARMACEUTICALS, INC., GENEOS THERAPEUTICS, INC.
Inventors:
Elizabeth Kennedy Duperret, Alfredo Perales Puchalt, David Weiner, Niranjan Y. Sardesai
Abstract: The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.
Type:
Grant
Filed:
August 23, 2019
Date of Patent:
October 19, 2021
Assignees:
H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Inventors:
Frederick L. Locke, Dario Altieri, Scott Antonia, Claudio Anasetti, Dmitry Gabrilovich
Abstract: In some embodiments, therapeutic treatments for a disease such as a cancer arc disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.
Type:
Application
Filed:
April 26, 2021
Publication date:
August 19, 2021
Applicant:
The Wistar Institute of Anatomy and Biology
Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Ebolavirus glycoproteinimmunogens are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against Ebolavirus are disclosed. Method of preventing Ebolavirus and methods of treating individuals infected with Ebolavirus are disclosed. Consensus Ebolavirus proteins are disclosed.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
August 17, 2021
Assignees:
The Trustees of the University of Pennsylvania, THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Inovio Pharmaceuticals, Inc.
Abstract: A method of obtaining a population of cells enriched in human polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) comprises isolating from a cell suspension those cells which express LOX-1 to provide a population of cells enriched with PMN-MDSCs. A method of monitoring the population of LOX-1+ cells in a cell-containing biological sample is useful for determining the efficacy of treatment or the metastasis or increasing progression of cancer. Other cell isolation and diagnostic methods are also described.
Type:
Grant
Filed:
May 31, 2016
Date of Patent:
July 27, 2021
Assignee:
The Wistar Institute of Anatomy and Biology
Inventors:
Dmitry I. Gabrilovich, Thomas C. Condamine
Abstract: Methods and compositions are described for enhancing tissue regeneration or wound repair in a mammalian subject comprising a composition comprising (a) a proline hydroxylase inhibitor component or molecule that increases or upregulates HIF1a and (b) a carrier component comprising a hydrogel.
Type:
Grant
Filed:
June 3, 2019
Date of Patent:
June 15, 2021
Assignees:
Northwestern University, The Wistar Institute of Anatomy and Biology
Inventors:
Phillip B. Messersmith, Iossif A. Strehin, Ellen Heber-Katz